logo
How changes to Covid-19 vaccine policy in the US may affect you

How changes to Covid-19 vaccine policy in the US may affect you

CNN4 days ago

The US Department of Health and Human Services, under Secretary Robert F. Kennedy Jr., has recently made significant changes to how Covid-19 vaccines are approved and the groups they are recommended for.
For the past few years, the federal government has broadly approved and recommended an updated Covid-19 shot for everyone ages 6 months and up each fall.
But last week, leaders from the US Food and Drug Administration outlined a new framework for the approval process for Covid-19 vaccines that could limit shots to older Americans and people at higher risk of serious Covid-19 infection. On Tuesday, Kennedy announced that the vaccine will no longer be among the recommended vaccines for pregnant women and healthy children on the US Centers for Disease Control and Prevention's immunization schedule.
These changes, made in unconventional ways, will probably affect access to and availability of Covid-19 vaccine shots for millions.
Under the framework outlined by FDA Commissioner Dr. Marty Makary and Dr. Vinay Prasad, the new director of the FDA's Center for Biologics Evaluation and Research, updated Covid-19 vaccines will probably be approved for everyone 65 and older and for people 6 months and older who have at least one underlying condition that puts them at 'high risk for severe Covid-19 outcomes.'
The CDC lists dozens of conditions that may contribute to higher Covid-19 risk, including asthma, cancer, diabetes, obesity and a history of smoking. These underlying conditions will make between 100 million and 200 million people in the US eligible for a Covid-19 vaccine under the new framework, the FDA leaders estimate.
Pregnancy is included on the list of factors that the CDC says have shown 'a conclusive increase in risk' for at least one severe Covid-19 outcome. Kennedy did not offer a specific reason behind the decision to stop recommending the Covid-19 for pregnant people in Tuesday's announcement, but the move appears to directly contradict the new framework outlined a week earlier.
For kids and adults younger than 65 who do not have an underlying condition, the FDA says it will require in-depth clinical trials before licensing new vaccines.
An independent group of advisers to the CDC – the Advisory Committee on Immunization Practices, or ACIP – is expected meet at the end of June to vote on Covid-19 vaccine recommendations, and they had already been weighing options for more targeted risk-based recommendations than the general guidelines issued in previous years.
Experts say next month's meeting could be a pivotal moment in the future of Covid-19 vaccine access, with much uncertainty around what will happen if the advisers recommend a different path forward than officials have outlined.
Maybe, but it may be more difficult – and expensive.
'Theoretically, one could find someone who would be willing to provide them the vaccine – and they may have to pay out of pocket to get it – but there's a lot of things that have to align for that to happen,' said Dr. Michelle Fiscus, a pediatrician and chief medical officer of the Association of Immunization Managers.
Health care providers, including pediatricians, may be able to provide the Covid-19 vaccine 'off-label' – but they'd need to have the vaccine in stock, which has become increasingly uncommon.
The vast majority of Covid-19 vaccinations happen at pharmacies. Pharmacists generally don't have the tools to verify medical history and whether an individual has a condition that makes them high-risk, so many of them could take patients at their word. But the recent announcements from the federal government may have a chilling effect on what providers are willing to do, experts say.
It's likely that people who are covered by public insurance such as Medicare and Medicaid and who meet the new FDA eligibility requirements will continue to have Covid-19 vaccines covered, experts say.
There's more uncertainty around how private insurance companies will choose to adjust coverage. Some of the conditions that the CDC lists as high-risk for Covid-19 – such as 'physical inactivity' – are loosely defined and may be left up to individual plans to interpret.
Under the Affordable Care Act, insurance companies are required to cover vaccines for adults if they've been recommended by ACIP. The committee also votes on whether vaccines should be added to the federal Vaccines for Children program, which provides vaccines to children who would not otherwise be able to afford them.
However, there's a gray area around what will happen if ACIP recommendations differ from CDC recommendations, experts say.
In a video posted on social media on Tuesday, Kennedy said that changes to the recommendations for children and pregnant people took effect that same day. As of Thursday morning, however, the CDC's recommended immunization schedule posted online had not changed.
Last week's editorial from Makary and Prasad said that the new framework for vaccine approval would be adopted 'moving forward.' The FDA officials say the new policy balances the need to swiftly approve vaccines – to have them ready by the fall respiratory virus season for the most vulnerable adults and children – against the need for more evidence before offering them to others.
Under this newly proposed framework, the FDA says, it will require additional evidence from vaccine manufacturers before approving updated Covid-19 shots for healthy kids and adults. The officials said those studies should last a minimum of six months, which would preclude any findings from influencing approvals in time for this fall.
The CDC's independent vaccine advisers meet at the end of June and are expected to vote on this fall's Covid-19 vaccine recommendations. Their decisions have guided vaccine policy in the US for decades, but it's unclear how much influence it will have over the newly announced changes. HHS still hasn't signed off on two of the three recommendations that were made at the group's last meeting, in April.
The Covid-19 vaccines that are currently available in the US have been approved by the FDA after rigorous analysis and are considered safe.
In their editorial outlining the new framework for Covid-19 vaccine approval, the FDA's Makary and Prasad said that 'the benefit of repeat dosing … is uncertain,' but they did not present evidence that Covid-19 vaccines themselves are unsafe.
The agency says it will approve vaccines for healthy kids and adults only after studies that prove that the shots can prevent symptomatic Covid-19 better than a placebo. However, the new plan doesn't take into account other effects of Covid-19 infections, such as long Covid.
These changes to Covid-19 vaccine policy limit opportunities to protect people who are at high risk, including young children and pregnant people, experts say
'We have vaccines that we know were critical in saving lives during the pandemic and we continue to see the morbidity and mortality from Covid-19,' Fiscus said. 'It's very concerning that people who would choose to protect themselves or their children with a vaccine may have that choice taken away.'
CNN's Brenda Goodman contributed to this report.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

From immigration law to business success: Navigating the challenges for foreign business in the U.S.
From immigration law to business success: Navigating the challenges for foreign business in the U.S.

Fast Company

time15 minutes ago

  • Fast Company

From immigration law to business success: Navigating the challenges for foreign business in the U.S.

As a U.S. business immigration attorney and founder of Grape Law Firm PLLC, I have worked with many foreign entrepreneurs who have achieved lasting success in the United States. Establishing and scaling a company here requires time, effort, and strategic planning to navigate a complex web of immigration regulations and compliance requirements. COMMON LEGAL HURDLES IN SECURING EMPLOYEE VISAS The primary challenge faced by businesspeople is securing a legal presence in the United States. This means obtaining the appropriate visa or status for both entrepreneurs and their essential personnel. However, the process of business immigration to the U.S. is often a challenging adventure. According to the 2024 CIS Ombudsman Annual Report, from initial market entry to business expansion—and even to permanent establishment—the complexities of business immigration affect entrepreneurs at every stage of their U.S. journey. They face significant challenges in documenting the viability of their enterprises to immigration officials while managing their immigration status to meet the changing needs of the business ecosystem. NAVIGATING VISA PATHWAYS FOR BUSINESS GROWTH As business immigration attorneys, one of our primary duties is to help our clients choose the most suitable visa for their business vision and goals. The selection of the appropriate visa is the foundation on which a successful application strategy is built and is an investment in the company's long-term growth. It is imperative for entrepreneurs to understand that various options exist for starting new businesses in the United States or expanding existing operations. Each visa category has its own distinct advantages and considerations based on differing business needs. For instance, the E‑1 Treaty Trader and the E‑2 Treaty Investor visas are viable options for entrepreneurs. These visa categories cater to foreign traders and investors who are citizens of treaty countries—countries that have treaty agreements with the U.S. Traders must engage in continuous trade with the United States, and the U.S. must be their primary trading partner. Conversely, investors must make substantial investments through new or existing enterprises. Both the E‑1 and E‑2 visas can support long-term, sustainable business ventures in the United States (each is valid for up to five years and can be extended indefinitely), provided that they spur economic progress in their respective industries and investment areas. Furthermore, the L‑1 Intracompany Transferee visa is an ideal choice for international companies planning to expand to the U.S. The L‑1 visa allows foreign companies to transfer their managerial or executive employees for new office openings, thereby facilitating the establishment of operations in the United States. However, a potential downside is that the L‑1 visa requires rigorous application preparation—a thorough case file must be compiled, followed by consistently detailed documentation of organizational development and business growth metrics, especially during the first three years of operations. A CASE IN POINT One case from our L‑1 visa practice perfectly illustrates these complexities. As a seasoned professional in the scaffolding industry, our client's initial L‑1 New Office visa application succeeded through careful preparation and a comprehensive five‑year business plan. However, the real challenges emerged during the extension phase. When she sought to extend her L‑1 visa with different legal counsel, she faced a rigorous Request for Evidence (RFE) from USCIS that scrutinized every aspect of her business operations. The RFE questioned not only the structure, but also its growth trajectory and staffing decisions—common challenges that many foreign businesses face in proving the legitimacy and sustainability of their operations. The industry's unique characteristics, including its project‑based nature and specialized staffing requirements, made it particularly challenging to conform to USCIS's traditional expectations for business development. Her case is a stark reminder for prospective entrepreneurs that experienced immigration counsel can provide needed guidance throughout the ups and downs of their U.S. immigration journey. Entrepreneurs must acknowledge that deciding on the right visa type is more than an entry ticket to the United States—a visa is the key to legal rights, business investments, and financial aspirations that influence one's life in the U.S. BUILDING A FOUNDATION FOR LONG-TERM SUCCESS The U.S. business immigration ecosystem is ever-changing and demands legal acumen in business planning—integrating proactive immigration solutions from the very beginning. To achieve lasting success, entrepreneurs need expert legal guidance to navigate the complex steps of immigration and adapt to any changes or updates in the immigration system. Beyond legal counsel, success often hinges on comprehensive preparation and strategic planning. Maintaining detailed business documentation from day one proves crucial for immigration success. Successful immigrant entrepreneurs often distinguish themselves through meticulous record-keeping of business transactions, employee contracts, and market analyses that demonstrate their enterprise's viability. Early strategic planning should include developing detailed business projections, establishing clear organizational structures, and creating systems for tracking achievements and metrics. These elements strengthen visa applications and create a foundation for sustainable growth. Networking within industry associations and chambers of commerce can provide valuable insights into immigration processes and business development. Furthermore, entrepreneurs who actively participate in their industry's ecosystem often find themselves better positioned to demonstrate their legitimacy to immigration authorities. This comprehensive approach, combining thorough documentation with strategic foresight, guarantees that immigration planning aligns with business goals while maintaining strict compliance with U.S. regulations. As we look to the future, business expansion into the United States and immigration to the country will only become more interlinked. In that regard, the aforementioned success story of our entrepreneur client is an excellent example—showcasing that viewing immigration not as a hurdle but as a strategic tool is essential for success. Always remember: proper planning, combined with expert guidance, can transform potential obstacles into opportunities for growth in the American market. The key to sustainable success lies in developing a nuanced understanding of how immigration pathways can support business objectives while ensuring compliance with regulatory requirements.

Employers Reluctant To Cover Obesity Meds, Lower Costs May Change This
Employers Reluctant To Cover Obesity Meds, Lower Costs May Change This

Forbes

time16 minutes ago

  • Forbes

Employers Reluctant To Cover Obesity Meds, Lower Costs May Change This

A new survey report from the International Foundation of Employee Benefit Plans shows continued reluctance by United States employers to cover glucagon-like peptide-1 drugs for weight loss. Going forward, however, lower net costs may induce better coverage by employers. Makers of GLP-1s for obesity are offering an array of discounts, some to insurers, others directly to patients. The IFEBP first conducted the survey in Oct. 2023 and again in May 2024. In the latest survey released ten days ago, employers revealed that 55% of them provide coverage of GLP-1s for diabetes only, while only 36% provide coverage for both diabetes and weight loss. And of those employers currently offering GLP-1 drug coverage solely for diabetes, just 17% are considering reimbursement of drugs for weight loss. Broadly speaking, the survey responses demonstrate that a large number of employers are still unwilling to reimburse GLP-1s for obesity. The weight loss therapeutics activate the body's receptors for GLP-1 on its own or in combination with GIP. When released by the gut, these natural hormones increase insulin delivery, suppress appetite, slow stomach emptying and increase the feeling of fullness. Perhaps what's driving continued reluctance to cover these products for weight loss is the overall impact that GLP-1s have on employers' pharmacy budgets. GLP-1 drugs used for obesity account for an average of 10.5% of total annual claims in the 2025 survey. In parts of the traditional health plans' market, we observe that some insurers are reconsidering their coverage of GLP-1s. Blue Cross Blue Shield, for example, just announced a reversal in its policy in which some plans offered coverage of GLP-1s for obesity. Starting in January 2026, BCBS will no longer cover these medicines for weight loss across the insurer's standard plans. At the same time, however, the large insurer Cigna announced it will begin capping out-of-pocket costs at $200 per month, starting next month, for patients using the obesity drugs Wegovy (semaglutide) and Zepbound (tirzepatide) through an add-on to its pharmacy benefit management plans. This is aimed at encouraging more employers to offer coverage of the drugs. It's unknown what the net cost to Cigna will be for the medicines. But presumably, the insurer has been able to reach a deal that's favorable financially, meaning a substantial reduction in net costs. It's possible in future that employers decide to revisit their coverage decisions if net costs decrease sufficiently, combined with more data showing the benefits of weight loss drugs when taken consistently and in conjunction with an appropriate dietary and exercise regimen. Also, the pharmaceutical firm Novo Nordisk announced last month a new partnership with CVS Caremark, the nation's largest pharmacy benefit manager, which grants coverage of Wegovy over its competitor Zepbound for customers who are insured for obesity medications. It's presumed that CVS was able to negotiate sizable rebates for Wegovy. CVS Caremark said that for insured patients, starting this July, Wegovy and Saxenda (liraglutide) will be the preferred GLP-1 medicines on its largest commercial formularies. This implies fewer access restrictions such as prior authorization, but also lower patient cost-sharing. It's unknown precisely what this means in terms of out-of-pocket costs for patients. But most patients with coverage for obesity drugs have monthly cost-sharing under $100. The arrangements reached by Cigna and CVS could help bring down net prices for employers for popular weight loss medicines. And at the same time, under the Inflation Reduction Act, the federal government is negotiating the prices of the GLP-1s Ozempic (semaglutide) and Wegovy. So-called maximum fair prices will be publicly posted in early 2026. These could reflect even steeper discounts. In addition to what payers are doing, Novo Nordisk is pursuing a direct-to-patient strategy to regain market share it has lost to drug maker Eli Lilly in the lucrative obesity drug market. Here, Novo Nordisk struck a deal in which CVS pharmacy will offer Wegovy for $499 a month for cash-paying customers who aren't insured for the medication. Since the Food and Drug Administration removed the active ingredients semaglutide and tirzepatide from its shortage list, the business model of selling directly at a considerable discount to the consumer has become popular for the two main manufacturers of obesity drugs. In 2024, Eli Lilly adopted a direct-to-consumer strategy for Zepbound, among other products, with its LillyDirect program. This service includes a DTC pharmacy and a referral network of in-person and telehealth clinicians. LillyDirect allows uninsured or underinsured individuals not on Medicaid or Medicare to purchase Zepbound product directly after obtaining the requisite prescription from their doctor. The firm recently extended the range of Zepbound products available through LillyDirect by adding high-dose vials at $499. Rival Novo Nordisk also launched a DTC option, NovoCare Pharmacy, two months ago. Patients not insured in the public sector who wish to have access to Wegovy can acquire the drug for an out-of-pocket cost of $499 per month, provided they have a prescription and make use of a designated specialty pharmacy. And, since the end of April, customers also pay a $499 monthly subscription when they obtain Wegovy from Ro and LifeMD, and $599 at Hims & Hers. While employers aren't yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future coverage decisions.

The Latest: Trump's tax cuts and tariff hikes spark concerns
The Latest: Trump's tax cuts and tariff hikes spark concerns

Washington Post

time16 minutes ago

  • Washington Post

The Latest: Trump's tax cuts and tariff hikes spark concerns

President Donald Trump faces the challenge of convincing Republican senators, global investors, voters and even Elon Musk that he won't bury the federal government in debt with his multitrillion-dollar tax breaks package. The response so far from financial markets has been skeptical. Meanwhile, Trump's doubling of tariffs on foreign steel and aluminum could hit Americans in an unexpected place: grocery aisles. The announcement Friday of a staggering 50% levy on those imports stoked fear that big-ticket purchases from cars to washing machines to houses could see major price increases.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store